You can see they have NOTHING on 100% recovery or the neuronal cascade of death. So not working on survivor recovery at all. The title says it all: 'management' NOT cure or recovery.
ON DEMAND: 9th Annual Lawrence M. Brass Stroke Symposium: Controversies in Stroke Management
Stroke is a leading cause of death and disability in the world. Acute stroke care and secondary prevention management have rapidly evolved. Practitioners are tasked to remain updated on the latest guidelines and recommendations in the management of stroke patients. Through case-based talks, faculty will discuss the complexities of stroke care in the era of stroke centers, state-of-the-art imaging, breakthroughs in acute therapies and modern-day medical therapies. Through case-based talks, faculty will discuss the complexities of stroke care in the era of primary and comprehensive strokes centers, state-of-the-art imaging, breakthroughs in acute therapies, advanced technical interventions for secondary prevention and modern-day medical therapies.
Included Topics/Speakers:
TIA Admissions vs Emergency Room Discharge: Somewhere in the middle? (Richa Sharma, MD)
Patent Foramen Ovale: Open and Close for Who? (Britton Keeshan, MD)
Technical Advances in Thrombectomy: Don’t Try this at Home. (Ryan Hebert, MD)
Vaso-occlusive Disease and Bypass Surgery: What, when and how? (Akli Zetchi, MD)
Intracranial Stenting for Stroke Prevention: Resurrection or Life Support? (Farhad Bahrassa, MD)
Cardiac Monitoring after Stroke: How long is long enough. (Reshma Narula, MD)
Blood Pressure Management in Acute Ischemic Stroke: Rekindling an Old Flame. (Nils Petersen, MD)
Atrial Appendage Occlusion: Who, Why and When. (James Freeman, MD)
Disparities in Stroke: In Our Backyard. (Rachel Forman, MD)
YNHH Presidential Address (Keith Churchwell, MD)
Atorvastatin 80mg. Is that All there is? Lipid Management 2.0 (Daniel Brooks, MD)
Coagulopathy Reversal in ICH: All that Glitters is not Gold. (Emily Gilmore, MD)
Hypercoagulable Testing in Stroke: Setting the Record Straight. (Alfred Lee, MD)
IV Alteplase v Tenecteplase: May the Best Lytic Win.(Adam Jasne, MD v Hardik Amin, MD)
TCAR vs CEA for Carotid Revascularization: New Kid on the Block(age). (Charles Matouk, MD v Jonathan Cardella, MD)
Bypassing Primary Stoke Centers: Are We There Yet? (Paul Lleva, MD v Neer Zeevi, MD)
Research In Progress: Ischemic Stroke (Kevin Sheth, MD)
Research in Progress: Hemorrhagic Stroke (Lauren Sansing, MD)
Research in Progress: Genetics and Stroke (Guido Falcone, MD)
Connecticut State Stroke Advisory Update (Chas Wira, MD)
- Evaluate workflow advances in the management of transient ischemic attack
- Summarize technical advances in mechanical thrombectomy
- Recognize the differences between IV alteplase and tenecteplase
- Explain why, when and what imaging is necessary for advanced stroke treatment
- Describe the approach to reversing coagulopathies in brain hemorrhage
- Identify the role of blood pressure optimization during the acute stroke time frame
Physicians - $50
Nurses/PAs/Allied Health Professionals - $25.00
Non-Yale
Residents/Fellows/Students† - complimentary, registration
required
Yale Residents/Fellows/Students† - complimentary,
registration required
YNHHS Faculty & Staff - complimentary, registration required
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The Yale School of Medicine designates this educational activity for a maximum of 7.50 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of
their participation in the Enduring Material activity.
Disclosure Policy
It
is the policy of Yale School of Medicine, Continuing Medical Education
(CME), to ensure balance, independence, objectivity, and scientific
rigor in all its educational programs. All individuals involved in the
development and presentation of Accredited Continuing Education
activities are required to disclose all financial relationship(s) with
ineligible companies that has occurred within the past 24 months; and
the opportunity to affect the content of CME about the products or
services of the commercial interests. This information is disclosed to
all activity participants prior to the commencement of the educational
activity.
No comments:
Post a Comment